Ann: Opthea Reports Half Year Results and Business Updates, page-14

The $11.7 mil interest relates to the (capitalised) expense attached to the Development Funding Agreement, for the 6 months, representing a little over 23%. This is In addition to the success payments (max 4 times or USD$680 mil if fully funded) in the agreement. Payments are not due until shortly after regulatory period and the obligation is recorded as a liability in the Balance Sheet.

Repayments consist of a milestone payment post approval, six annual fixed success payments and variable success payments consisting of 7% of net sales - all until the 4 times cap is reached, when the obligation is satisfied.

The DFA has a lien placed on most of Optheas assets and contains clauses which restrict the type of funding Opthea can enter into.

You are correct in saying that the '$' should not be present in the description of the loss per share